Fingolimod

Study	Type of data	Exposure measurement	Outcome assessment	Adjustment
Karlsson (control exposed to IFN), 2014	retrospective cohort	Patients received treatment provided by the investigator in clinical trial.	Not specified.	None
Karlsson (control unexposed, sick), 2014	retrospective cohort	Patients received treatment provided by the investigator in clinical trial.	Not specified.	None
Nguyen (control exposed to IFN), 2019	prospective cohort	Data in the MSBase registry, including prospective pregnancy data, is entered in real time or near real time, as part of routine clinical visits. Information collected included: disease-modifying therapies exposure before and during pregnancy.	Data in the MSBase registry, including prospective pregnancy data, is entered in real time or near real time, as part of routine clinical visits. Information collected included pregnancy outcomes.	None
Nguyen (control unexposed, sick), 2019	prospective cohort	Data in the MSBase registry, including prospective pregnancy data, is entered in real time or near real time, as part of routine clinical visits. Information collected included: disease-modifying therapies exposure before and during pregnancy.	Data in the MSBase registry, including prospective pregnancy data, is entered in real time or near real time, as part of routine clinical visits. Information collected included pregnancy outcomes.	None
Pauliat, 2020	prospective cohort	Maternal information on medication exposure (indication, timing in pregnancy, duration, dose and concomitant medication) were collected at initial contact.	Follow-up was achieved through a structured telephone interview or mailed questionnaire to the patient or her healthcare professional. Two independent specialists blinded to information on drug exposure, classified congenital anomalies as major or minor.	Control group was matched according to center, year of contact, and maternal age. Intrauterine deaths adjusted for center, maternal age, tobacco smoking, and folic acid consumption.

master protocol